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Abstract
Background Anorexia is a common symptom among cancer patients and contributes to malnutrition and strongly impinges
on quality of life. Cancer-induced anorexia is thought to be caused by an inability of food intake-regulating systems in the
hypothalamus to respond adequately to negative energy balance during tumour growth. Here, we show that this impaired
response of food-intake control is likely to be mediated by altered serotonin signalling and by failure in post-transcriptional
neuropeptide Y (NPY) regulation.
Methods Two tumour cachectic mouse models with different food intake behaviours were used: a C26-colon adenocarci-
noma model with increased food intake and a Lewis lung carcinoma model with decreased food intake. This contrast in food
intake behaviour between tumour-bearing (TB) mice in response to growth of the two different tumours was used to
distinguish between processes involved in cachexia and mechanisms that might be important in food intake regulation. The
hypothalamus was used for transcriptomics (affymetrix chips).
Results In both models, hypothalamic expression of orexigenic NPY was significantly higher compared with controls,
suggesting that this change does not directly reflect food intake status but might be linked to negative energy balance in
cachexia. Expression of genes involved in serotonin signalling showed to be different between C26-TB mice and Lewis lung
carcinoma-TB mice and was inversely associated with food intake. In vitro, using hypothalamic cell lines, serotonin repressed
neuronal hypothalamic NPY secretion while not affecting messenger NPY expression, suggesting that serotonin signalling can
interfere with NPY synthesis, transport, or secretion.
Conclusions Altered serotonin signalling is associated with changes in food intake behaviour in cachectic TB mice. Serotonins’
inhibitory effect on food intake under cancer cachectic conditions is probably via affecting the NPY system. Therefore, serotonin
regulation might be a therapeutic target to prevent the development of cancer-induced eating disorders.
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Introduction
Anorexia and consequently a reduced caloric intake1 affects a
majority of all cancer patients.2 Cancer patients with good
appetite and adequate caloric intake have higher survival
rates than patients who suffer from anorexia and hence a
lower energy intake.3,4 Cancer-induced anorexia is considered
to be predominantly caused by failure of orexigenic and
anorexigenic food intake-regulating systems in the hypothala-
mus to respond adequately to changes in energy balance.5
This merits further elucidation of the specific mechanisms
involved in this hypothalamic resistance to peripheral
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neuroendocrine triggers. Several food intake-regulating systems
have been mentioned to play a role in the onset of hypotha-
lamic resistance, including the orexigenic triggers neuropeptide
Y (NPY) and ghrelin, and anorexigenic melanocortin and CART
systems. Cancer anorexia often develops during the progression
of cachexia,6 and the combined clinical picture is often called
anorexia–cachexia syndrome.7 Cachexia is a complex metabolic
syndrome associated with underlying illness and is characterized
by progressive loss of muscle (muscle wasting) with or without
loss of fat mass. This results in weight loss, a reduced quality
of life and a shortened survival time.6,8,9 Although anorexia is
often linked to cachexia and likely to be initiated by similar
pathologies (tumour growth), it is unclear as to what extent
anorexia and the metabolic alterations of cachexia affect each
other, or to what extent these are distinct entities with their
own pathology. Here, we use two tumour-bearing (TB) mouse
models displaying similar development of cachexia. At the
same time, they show opposite effects on food intake in
response to tumour growth. This provides opportunities to
disentangle processes involved in anorexia from those causing
cachexia. By applying transcriptomics, we show that tumour-
induced cachexia is associated with several distinct changes in
food-intake, regulating mediators in the hypothalamus that
appear to be independent of food intake status. Furthermore,
we found alterations in hypothalamic serotonin signalling, and
these changes were inversely associated with food intake. In
addition, we used hypothalamic cell lines to explore the
mechanisms involved in the interaction between serotonin
and the NPYergic system.
Materials and methods
Lewis lung tumour model (LLM)
C57Bl/6 male mice (Harlan, Barcelona, Spain), weighing
approximately 20 g, were placed on a standard ad libitum diet
(Panlab, Barcelona, Spain) and had free access to water. Lewis
Lung carcinoma (LLC) cells were obtained from exponential
tumours. Under general anaesthesia, 0.5 × 106 cells were
injected intramuscularly in the hind leg. Four groups were
included: C, control mice sacrificed at Day 14 (n = 6); TB-10,
TB mice sacrificed at Day 10 (n = 6); TB-14, TB mice sacrificed
at Day 14 (n = 8), and TB-17, TB mice sacrificed at Day 17
(n= 6). Body weight and food intake were measured daily. At
the day of sacrifice, mice were anesthetized with a ketamine/
xylazine mixture (i.p., Imalgene® and Rompun®, respectively),
and blood was collected by cardiac puncture.
C26 colon adenocarcinoma tumour model
Part of the data (Figure 1A) from this experimental arm
with C26 TB mice have been published previously10 but
are briefly described again here for easy comparison with
Lewis lung TB mice.
Male CDF1 (BALB/cx DBA/2) mice aged 6–7weeks
(Harlan Nederland, Horst, The Netherlands) were placed on
a standard ad libitum diet (AIN93M, Research Diet Services,
The Netherlands) and had free access to water.
Murine C26 adenocarcinoma cells were cultured and
suspended as described previously.11 Under general anaesthesia
(isoflurane/N2O/O2), 1 × 106 tumour cells in 0.2mL Hank’s
balanced salt solution (HBSS) were inoculated subcutaneously
into the right inguinal flank. Controls were sham-injected with
0.2mL HBSS.
Two groups were included: C, control mice (n=6) and TB (n=9).
Body weight and food intake were measured three times a
week. At Day 19, blood was collected by cardiac puncture
under general anaesthesia.
In both tumour models, animals were individually housed
1week before start of the experiment in a climate-controlled
room (12:12 dark-light cycle, 21°C ± 1°C).
After sacrifice, brain, hypothalamus, tumour, organs, and
lower leg skeletal muscles (non-tumour leg) were weighted
and frozen in liquid nitrogen and were stored at 80°C.
Carcass weight was calculated by body weight at day of
section minus tumour weight.
All experimental procedures were made in accordance
with the European community guidelines for the use of
laboratory animals and complied with the principles of good
laboratory animal care.
Cell culture and reagents
Murine-derived hypothalamic neuronal cell lines hypoE-46
and hypo-A2/12 (CELLutions Biosystems Inc., Canada) were
grown and maintained in Dulbecco’s modified eagle’s
medium (DMEM) supplemented with 10% heat-inactivated
foetal calf serum, 100unit/mL penicillin and 100μg/mL strep-
tomycin at 37°C under 5.0% CO2. Cells were grown in mono-
layers to 90% confluency. Then, medium was replaced by
serum-free DMEM containing penicillin and streptomycin.
After 4h, cells were exposed to serotonin (100μg/mL,
1μg/mL, 10ng/mL, or 100pg/mL) for 24h or 60mM KCl for
15min. After exposure, supernatant was collected and used for
NPY measurements using an enzyme immunoassay (NPY EIA,
Phoenix Pharmaceuticals, CA, USA). Cells were homogenized in
40mM Tris, 1mM ethylenediaminetetraacetic acid, 5mM
ethylene glycol tetraacetic acid, and 0.50% Triton X-100.
Homogenates were used to measure protein content (Pierce
Bicinchoninic acid Rockford, IL, USA). Serotonin cytotoxicity
was determined by measuring lactate deshydrogenase leakage
and effects on cell viability using a tetrazolium salt XTT assay
(Roche Diagnostics, Mannheim, Germany).
Serotonin levels
Hypothalamic samples were used for microarray experi-
ments, while remaining brain parts were used to determine
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serotonin levels. Brains were homogenized in 1mL containing
in 40mM Tris, 1mM ethylenediaminetetraacetic acid, 5mM
ethylene glycol tetraacetic acid, and 0.50% Triton X-100.
Serotonin levels were measured using enzyme-immunoassay
kits (BAE-5900, LDN, Nordhorn, Germany) and were
corrected for the amount of protein (nanodrop spectropho-
tometer, Thermo Scientific).
Statistics
Data were analysed by statistical analysis of variance
followed by a post hoc Bonferroni test or by a Student’s t-test.
Differences were considered significant at a two-tailed
P< 0.05. Statistical analyses were performed using GraphPad
Prism 5. For statistical analysis of microarray data, see micro-
array section.
Microarray studies
Total RNA from the hypothalamus was isolated by using
RNeasy lipid tissue kit (Qiagen, Venlo, The Netherlands).
RNA concentrations were measured by absorbance at
260 nm (nanodrop). RNA quality was checked using the RNA
6000 n assay on the Agilent 2100 bioanalyser (Agilent
Figure 1 Effect of tumour inoculation on food intake, carcass weight and muscle, and fat weight in two cachectic models. (A) Time course of change
in food intake in mice bearing the C26 tumour. (B) Carcass weight of C26 tumour-bearing mice at Day 19. (C) Weight of m. gastrocnemius and
epididymal fat pads in C26 tumour-bearing mice at Day 19. (D) Time course of change in food intake of tumour-bearing mice bearing the Lewis
lung carcinoma. (E) Carcass weight of Lewis lung carcinoma tumour-bearing mice at Days 10, 14, and 17. (F) Weight of m. gastrocnemius and
epididymal fat pads in Lewis lung carcinoma tumour-bearing mice at Days 10, 14, and 17. *Significantly different from C (P< 0.05). Data are
expressed as mean ± SEM. C, sham-injected control; TB, C26-injected tumour bearing; C-14, sham-injected control sacrificed at Day 14; TB-10, Lewis
lung carcinoma-injected tumour bearing sacrificed at Day 10; TB-14, Lewis lung carcinoma-injected tumour bearing sacrificed at Day 14; and TB-17,
Lewis lung-injected tumour bearing sacrificed at Day 17. Carcass weight was calculated by body weight at day of section minus tumour weight.
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Techologies, Amsterdam, The Netherlands) according to the
manufacturer’s protocol. For each mouse, total RNA (100ng)
was labelled using the Ambion WT expression kit (Life Technolo-
gies, Bleiswijk, The Netherlands). Microarray experiments were
performed by using affymetrix mouse gene ST 1.1.
From the C26 model experiment, four control samples and
five samples from TB mice were included in this experiment;
however, one control sample gave multiple spots on the array
and was therefore excluded from analysis. The Lewis lung
experiment included four controls, five TB-10, seven TB-14,
and six TB-17 samples.
Array data were analysed using an in-house, online
system.12Briefly, probesets were redefined according to Dai
et al.13 using remapped computable document format ver-
sion 15.1 based on the Entrez gene database. In total, these
arrays target 21 225 unique genes. Robust multi-array analy-
sis was used to obtain expression values.14,15 We only took
genes into account that had an intensity >20 on at least
two arrays, had an interquartile range throughout the sam-
ples of >0.1, and had at least seven probes per gene. Genes
were considered differentially expressed at P< 0.05 after
intensity-based moderated t-statistics.16 Further functional
interpretation of the data was performed through the use
of Ingenuity Pathway Analysis (IPA) (Ingenuity® Systems,
www.ingenuity.com). Canonical pathway analysis identified
the pathways from the IPA library of canonical pathways that
were most significant to the data set. Genes from the data set
that met the cut-off of 1.3-fold change and P-value cut off of
0.05 and were associated with a canonical pathway in the
ingenuity knowledge base were considered for the analysis.
To list up genes involved in food intake regulation, genes
included in gene ontology (GO) 0002023, GO 0007631, GO
0008343, GO 0060259, and GO 0042755 (food intake, feeding
behaviour, and eating behaviour) were analysed (gene ontology,
tool for the unification of biology. The Gene Ontology
Consortium (2000) Nature Genet. 25: 25–29). Also, genes
pro-opiomelanocortin (ID: 18976), growth hormone (ID:
14599), Sst (ID: 20604), and pro-melanin-concentrating hormone
(PMCh) (ID: 110312) were additionally looked at,since they also
have been described to play a role in food intake behaviour.17
Array data have been submitted to the gene expression
omnibus, accession numbers GSE44082 (C26 tumour) and
GSE57190 (Lewis Lung tumour and hypothalamic cell lines).
Data set containing the array data on hypothalamic tissues
of C26 TB mice has been published previously.10
Results
Body weight and food intake
In both tumour models, TB mice showed a lower carcass
weight, muscle weight, and white adipose fat mass (Figure 1)
compared with their healthy controls, reflecting that cachexia
was present in mice bearing either the C26 or the Lewis Lung
tumour.
Food intake changes in TB animals were found to differ
between the two cachectic models. Mice bearing the C26
tumour was found to increase their food intake synchronously
to loss of body weight,10 while mice bearing the LLC showed a
lowered food intake from Day 7 after tumour inoculation
compared with controls (Figure 1 A and D). These opposing
changes in food intake in TB mice in response to tumour
growth of the two different tumours are used to disentangle
shared mechanisms of cachexia from those important for food
intake regulation.
Microarray analysis of the hypothalamus:
comparison of C26 and LLM
Expression of genes involved in food intake was analysed to
determine if these could explain the opposing changes in
food intake between C26 TB and LLC TB mice. A list of genes
involved in food intake was generated by using GO categories
involved in food intake regulation (M&M). Fold changes of
expression of orexigenic and anorexigenic genes were com-
pared between the two tumour models (Figure 2A). Interest-
ingly, changes in gene expression of important mediators of
food intake regulation, NPY, AgRP, and pro-opiomelanocortin
showed to be similar in C26 TB mice and LLC TB mice com-
pared with their controls even though food intake behaviour
was different between the two models. Furthermore, gene
expression of oxytocin showed to be altered in TB mice com-
pared with controls and differed between the two models.
In addition, analysis of highly up-regulated genes (top 30
up-regulated genes in TB mice compared with controls) in
both tumour models was performed. There was a strong
overlap of genes that was highly up-regulated in both C26 TB
and LLC TB mice compared with their controls, including NPY
and AgRP. Furthermore, expression of inflammatory markers
lipocalin 2, leucin-rich α2-glycoprotein 1, secretoglobin 3a1,
and oncostatin M receptor showed to be highly up-regulated
in TB mice in both models. Taken together, this suggests that
major alterations in hypothalamic mechanisms are similar for
both tumour models.
Microarray analysis of the hypothalamus: serotonin
signalling
We hypothesized serotonin to play a crucial role in the
opposing food intake behaviour between the C26 tumour
and LLC tumour model. Therefore, expression levels of genes
involved in serotonin signalling were compared between the
two tumour models. C26 TB mice expressing compensatory
eating behaviour in response to weight loss showed altered
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serotonin signalling and lower brain serotonin levels com-
pared with their controls. In LLC TB mice, genes involved in
serotonin signalling showed a different expression pattern
compared with C26 TB mice. Expression of tryptophan
hydroxylase (tph) was strongly down-regulated in C26 TB
mice compared with controls, while expression of this gene
was not different from controls in LLC TB mice. Expression
of ddc and vmat, genes involved in serotonin synthesis and
Figure 2 Heat map representation of gene expressions in the hypothalamus in C26 and Lewis lung carcinoma tumour-bearing mice. (A) Fold
changes of orexigenic and anorexigenic genes relative to their control group were calculated and compared between C26 and Lewis lung carcinoma
tumour-bearing mice. (B) Top 30 up-regulated genes in C26 tumour-bearing mice compared with their controls and top 30 up-regulated genes in
Lewis lung carcinoma tumour-bearing mice compared with their controls. Twelve genes were overlapping between the C26 and Lewis lung carci-
noma tumour model. Each row represents a gene, and each column represents a group of animals. Red colour indicates genes that were higher
expressed as controls, and green colour indicates genes that were lower expressed as the controls. Black indicates genes whose expression was
similar to compared with controls. ID: Entrez ID. C, sham-injected control; TB, C26-injected tumour-bearing; C-14, sham-injected control sacrificed
at Day 14; TB-10, Lewis lung carcinoma-injected tumour bearing sacrificed at Day 10; TB-14, Lewis lung carcinoma-injected tumour bearing
sacrificed at Day 14; and TB-17, Lewis lung carcinoma-injected tumour bearing sacrificed at Day 17.
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serotonin release, respectively, showed to be down-regulated
in C26 TB mice, whereas LLC TB mice showed higher expres-
sion of these genes (Figure 3B). Serotonin brain levels in LLC
TB mice showed to be slightly elevated at Day 10, just after
the onset of anorexia, while levels were lower in C26 TB mice
compared with controls (Figure 3C).
Hypothalamic cell lines: effect of serotonin on
messenger neuropeptide Y and neuropeptide Y
secretion
Murine-derived hypothalamic cell lines hypoE-46 and hypoA-
2/12 were 24 h exposed to serotonin (100 pg/mL–100μg/
mL). Serotonin showed to decrease NPY secretion in the
hypoE-46 cells, while it did not have any effect on messenger
NPY (Figure 4). In hypoA-2/12 cells, serotonin did not have an
effect on either NPY secretion or NPY gene expression. Basal
expression level of serotonin receptors between the two cell
lines showed to be significantly different for receptors 5HT1b,
5HT1d, 5HT2a, and 5HT2b (Table 1). The effect of serotonin
on gene expression of 5HT receptors was not different
between the two cell lines, except for 5HT2b, which was
down-regulated in hypoE-46 cells and up-regulated in
hypoA-2/12 cells after serotonin exposure.
Discussion
Cancer anorexia has been explained by an inability of the
hypothalamus to respond adequately to triggers from the
periphery during a situation of negative energy balance.18
Here, we show that this impaired response of food-intake
control is associated with altered serotonin signalling and
probably stunted NPY post-transcriptional regulation in the
hypothalamus. In addition, this serotonin regulation and
brain serotonin levels were inversely associated with food
intake. In vitro, serotonin was found to modulate NPY release
by hypothalamic neurons. Taken together, this suggests that
serotonin is likely to play a crucial role in the failure of the
NPYergic system during cancer anorexia.
By comparing two cancer models sharing common charac-
teristics of tumour-induced muscle wasting and fat loss while
displaying opposite effects on food intake behaviour, we
are able to disentangle anorexia from cachectic processes.
Peripheral markers for cachexia reflecting weight loss, muscle
loss, and fat loss were comparable between the two tumour
models. In addition, the most prominently (top 30-based)
induced hypothalamic genes compared with healthy controls
showed to be similar between the two models. This suggests
that there is a common subset of genes that is strongly
induced during tumour growth and progression of cachexia,
despite the differences in type of tumour, inoculation site,
strain of mice, and independent from effects on food intake
behaviour. These changes might represent markers for
cachexia or tumour-induced inflammation as gene expression
of strongly up-regulated inflammatory genes was overlapping
between the two models.
Interestingly, also a majority of genes involved in food
intake regulation showed to be similar between the models,
even though ultimate effects on food intake were different
for the two models. Food intake and drive to eat are the out-
comes of numerous metabolic, physiological, and behavioural
cues including satiety, hunger and reward, and learning.
Therefore, changes on individual genes are difficult to inter-
pret, as the impact on food intake is not similar between
these single genes. Furthermore, it might be that, considering
the complexity of food intake regulation, by using GO classi-
fication on food intake behaviour, some genes are ignored
that might be important as well. Finally, a limitation of the
current set-up is that we study expression in the hypothala-
mus only. Although the hypothalamus is a crucial site of food
intake regulation, not all processes involved in food intake
are regulated in the hypothalamus.19 Gene expression of
NPY, one of the most potent food stimulating neuropeptides
in the hypothalamus,20 showed to increase in both C26 TB
and LLC TB mice and was among the strongest induced genes
in both models. This suggests that expression of NPY in
cachectic TB mice is independent of food intake status. NPY is
considered to act as a sensor and regulator of energy balance
by altering food intake in energy deficits, which is supported
by findings that NPY is stimulated in conditions of negative
energy balance like food restriction,21 food deprivation,22,23
and exercise.24,25 Several studies have shown that in cachectic
TB rodents, NPY messenger RNA (mRNA) in the hypothalamus
is elevated.26–29 However, this elevation of mRNA NPY does
not reflect food intake behaviour27,29 and does not correspond
to NPY levels in the hypothalamus.27 In contrast to these
elevated messenger NPY levels, anorectic TB rodents have
lower paraventricular nucleus (PVN) hypothalamic NPY
levels30,31 and lower NPY immunostaining of fibres innervating
various hypothalamic nuclei.32 On the other hand, mice bearing
an A375 tumour that do not suffer from cachexia and weight
loss did not show this elevation of NPYmRNA,26 suggesting that
cachexia is an important trigger in stimulation of NPY mRNA.
This might explain that in both the C26 model and LLC
model, messenger NPY was highly up-regulated in TB mice
compared with controls, despite their difference in food
intake behaviour. Consequently, we hypothesize that failure
of the NPYergic system taking place at a post-transcriptional
level, for example, by impaired translation, synthesis, transport,
or secretion, plays a role in the development of tumour-
induced anorexia.
In this study, we also found serotonin signalling to be
differently regulated between two types of tumour-induced
cachexia models, in addition to their opposed effects on food
intake behaviour. In C26 TB mice, serotonin signalling was
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Figure 3 Serotonin signalling in C26 and Lewis lung carcinoma tumour-bearing mice. (A) Schematic view of genes involved in serotonin signalling.
(B) Heat map of fold changes of expressions of genes involved in serotonin signalling. (C) Serotonin level in brain relative to control mice in C26 and
Lewis lung carcinoma tumour-bearing mice. Values are expressed as mean ± SEM. C, sham-injected control; tumour bearing, injected with
1 × 106 tumour cells; DNTP, 7,8-dihydroneopterin triphosphate; 6PTS, 6-pyruvoyl-tetrahydropterin; q-dbt, q-dihydrobiopterin; TRP, tryptophan;
5HT, 5-hydroxytryptamine (serotonin); MAO, monoamine oxidase; and ALDH, aldehyde dehydrogenase.
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strongly down-regulated and inversely associated with an
increased food intake. Anorectic Lewis lung TB mice displayed
less pronounced changes in transcript levels of gene involved
in serotonin signalling compared with C26 TB mice. Moreover,
transcriptional regulation was different from mice-bearing
C26 tumour. Furthermore, brain serotonin levels were signifi-
cantly elevated in TB mice at Day 10 compared with controls,
shortly after the manifestation of anorexia. This effect was
less clear at Days 14 and 17, suggesting that effects on seroto-
nin are more prominent during the initial stages of anorexia
development. It has been postulated that cancer anorexia
develops by waves of brain activation,33 each of them not
necessarily mediated by the same mediators. It could be that
serotonin might play a role in the initiation of anorexia. Hypo-
thalamic serotonin is an important mediator in the regulation
of satiety and hunger.34 In cancer-induced anorexia, serotonin
is considered a key player in the induction of anorexia.35,36 In
rodents, tumour-driven elevation of hypothalamic serotonin
has been associated with reduced food intake.31,37,38 Further-
more, this elevation of serotonin was not present in the pair-
fed control group, meaning that reduced food intake itself
does not result in an elevation of hypothalamic serotonin. In
Figure 4 Effect of serotonin on messenger neuropeptide Y and neuropeptide Y secretion in hypothalamic cells. Murine-derived hypothalamic cell
lines were 24 h exposed to various concentrations serotonin. Potassium chloride was used to depolarize cells (positive control). (A) Effect of sero-
tonin on NPY secretion in hypoE-46 and hypoA-2/12 cells. (B) Effect of serotonin on neuropeptide Y gene expression in hypoE-46 and hypoA-2/12
cells. *Significantly different from C (P< 0.05). Data are expressed as mean ± SEM.
Table 1 Effect of serotonin on gene expression in hypothalamic cells
Gene
HypoE-46 HypoA-2/12
ID Description
Control 100 μg 5HT Control 100 μg 5HT
Htr1a 12.0 12.5 11.8 12.7 15 550 5-Hydroxytryptamine receptor 1A
Htr1b 19.0 17.6 41.8b 31.9 15 551 5-Hydroxytryptamine receptor 1B
Htr1d 20.2 13.0a 15.8b 14.5 15 552 5-Hydroxytryptamine receptor 1D
Htr1f 17.3 15.7 16.7 15.9 15 557 5-Hydroxytryptamine receptor 1F
Htr2a 32.1 24.4a 104.0b 213.7c 15 558 5-Hydroxytryptamine receptor 2A
Htr2b 18.6 16.2 12.9b 16.4 15 559 5-Hydroxytryptamine receptor 2B
Htr2c 9.3 9.5 9.0 10.3 15 560 5-Hydroxytryptamine receptor 2C
Htr3a 10.2 9.5 9.6 10.5 15 561 5-Hydroxytryptamine receptor 3A
Htr3b 12.1 13.1 12.1 11.9 57 014 5-Hydroxytryptamine receptor 3B
Htr4 20.9 19.9 19.0 19.2 15 562 5-Hydroxytryptamine receptor 4
Htr5a 13.9 14.8 13.5 14.0 15 563 5-Hydroxytryptamine receptor 5A
Htr5b 21.6 18.3 18.5 17.7 15 564 5-Hydroxytryptamine receptor 5B
Htr6 21.6 19.4 21.9 19.8 15 565 5-Hydroxytryptamine receptor 6
Htr7 17.9 17.8 13.9 14.7 15 566 5-Hydroxytryptamine receptor 7
Murine-derived hypothalamic cell lines hypoE-46 were 24 h exposed to various concentrations serotonin. Gene expression of serotonin
receptors (5HTRs) were determined by using microarrays.
aSignificantly different from control in hypoE-46 cells.
bSignificantly different from hypoE-46 cells basal expression.
cSignificantly different from control in hypoA-2/12 cells (P> 0.01).
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humans, a practical and non-invasive method to measure site-
specific changes on serotonergic activity in the hypothalamus
is not yet available, but increased levels of tryptophan, the
precursor of serotonin, have been measured in cerebral spinal
fluid of cancer anorectic patients.39
The exact mechanism on how serotonin is able to regulate
food intake is not yet understood. A cross interaction of sero-
tonin with NPYergic system has been discussed.31 Serotonin
signalling is negatively associated with NPY activity.40–42
Active lowering of serotonin levels results in increased NPY
levels,43 while induction of 5-HT signalling showed to reduce
NPY levels in rat hypothalamus.44 More importantly, seroto-
nin is able to repress food intake, despite weight loss-induced
elevation of messenger NPY,45 suggesting that serotonin
might act as an interfering factor between transcription and
NPY secretion. Therefore, we hypothesized that serotonin
might interfere with NPY signalling at a post-transcriptional
level. In this way, it could play a role in post-transcriptional
failure of the NPY system during certain forms of cancer.
To determine serotonin’s ability to repress NPY secretion,
we used two murine-derived hypothalamic cell lines. We
showed that serotonin is able to reduce NPY secretion in
hypoE-46 cells, a cell line suggested to originate from the
PVN,46 without affecting NPY gene expression, supporting
the hypothesis that serotonin acts post transcriptionally.
Serotonin did not have an effect on NPY secretion in
hypoA-2/12 cells, a cell line suggested to originate from the
arcuate nucleus (ARC) or supraoptic nucleus.47 In lean and
obese Zucker rats, increased levels of serotonin, induced by
chronic administration of fluoxetine, resulted in reduced food
intake and reduced levels of NPY in the PVN, but not in the
ARC and other areas of the hypothalamus.40 This suggests
that NPY release by PVN neurons is more sensitive to seroto-
nin and might explain the difference in response to serotonin
between the two cell lines.
The two cell lines did not show differences in their general
response to serotonin as reflected by expression of genes
involved in serotonin signalling. An exception to this was
the effect of serotonin on expression of the 5HT2a receptor,
which was down-regulated in response to serotonin in the
hypoE-46 and up-regulated in the hypoA-2/12 cell line. More-
over, basal expression of 5HT1b and 5HT2a, and 5HT2b and
5HT2c differed between the two cell lines. In the ARC nucleus,
serotonin has been reported to inhibit NPY release by hyperpo-
larization of AgRP/NPY neurons via 5HT1B receptors.48 The role
of 5HT2 receptors might be a target for further research on
their role in NPY regulation. However, as NPY secretion is via
granule exocytosis,49 also, a receptor-independent process like
serotonylation of guanosine triphosphatases (GTPases) might
be implicated. Serotonylation is a process, where intracellular
serotonin is able to activate small GTPases via transamination.
Dependent on the type of GTPases that are activated, several
processes dependent on granule exocytosis can be affected,
which has been reported for insulin secretion by pancreatic β
cells50 or platelet aggregation.51
In this study, we provide evidence that cancer anorexia
might be due to post-transcriptional failure of the NPYergic
system in the hypothalamus to respond to increased energy
requirement in cancer cachexia. We show that serotonin is
able to affect NPY secretion in vitro. In addition, serotonin
signalling is found to be altered in TB mice, suggesting that
serotonin might play a crucial role in failure of hypothalamic
NPY signalling and subsequently the development or
sustainment of cancer anorexia.
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